SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferencePresentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET
June 9, 2020
 · 
1 min read
BioForest
Clinical Catch-Up: May 31-June 5
June 5, 2020
 · 
10 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics to Present at the Jefferies 2020 Healthcare ConferencePresentation scheduled for tomorrow, Wednesday, June 3, 2020, at 10:00 AM ET
June 2, 2020
 · 
1 min read
Drug Development
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
May 29, 2020
 · 
5 min read
Pharm Country
TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting
May 15, 2020
 · 
3 min read
Pharm Country
TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
May 14, 2020
 · 
5 min read
Deals
TG Therapeutics Announces Proposed Public Offering of Common Stock - May 14, 2020
May 14, 2020
 · 
4 min read
Business
BioSpace Movers & Shakers, May 15
May 14, 2020
 · 
4 min read
 · 
Alex Keown
Pharm Country
TG Therapeutics Announces Data Presentations at Upcoming Medical Meetings
May 14, 2020
 · 
5 min read
Business
TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
May 11, 2020
 · 
10 min read
Business
TG Therapeutics Strengthens Executive Team with the Addition of Owen A. O’Connor, MD, PhD, as Chief Scientific Officer
May 8, 2020
 · 
6 min read
Pharm Country
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility$40 million of which came from longtime shareholder, RA Capital Management
May 6, 2020
 · 
5 min read
Drug Development
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
May 5, 2020
 · 
8 min read
Bio NC
Clinical Catch-Up: April 27-May 1
May 1, 2020
 · 
11 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
May 1, 2020
 · 
7 min read
Business
BioSpace Movers & Shakers, May 1
April 30, 2020
 · 
5 min read
 · 
Alex Keown
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS